Rheumatology Xagena

Xagena Mappa
Medical Meeting

Search results for "Baricitinib"

Eli Lilly and Incyte have announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of Baricitinib in patients with active rheumatoid arthritis. Ba ...

In a phase III, double-blind 24-week study, RA-BUILD, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to grea ...